Ulrich Duehrsen

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Blood · 2010 · 88 citations

Medicine, Oncology, Pharmacotherapy +16

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Michael Pfreundschuh, Marita Kloess, Rudolf Schmits et al. · Blood · 2005 · 56 citations

Medicine, Geriatric Medicine, Oncology +8

Cloned stromal cell lines derived from human Whitlock/Witte-type long-term bone marrow cultures.

J Novotný, Ulrich Duehrsen, K Welch et al. · PubMed · 1990 · 42 citations

Life Sciences, Biotechnology, Cell Biology +12

Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Michael Pfreundschuh, Marita Kloess, Samira Zeynalova et al. · Blood · 2006 · 30 citations

Medicine, Hematology, Oncology +10

Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3 Protocol).

Peter Dreger, R. Busch, Stephan Stilgenbauer et al. · Blood · 2004 · 10 citations

Medicine, Hematology, Oncology +14